SHEZF's Quick Ratio is ranked worse than 57.65% of 994
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs SHEZF: 1.21
Shenzhen Hepalink Pharmaceutical Group Co (OTCPK:SHEZF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Shenzhen Hepalink Pharmaceutical Group Co Quick Ratio Related Terms
Shenzhen Hepalink Pharmaceutical Group Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co Quick Ratio Chart
Shenzhen Hepalink Pharmaceutical Group Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Hepalink Pharmaceutical Group Co Quick Ratio vs Drug Manufacturers Industry
Shenzhen Hepalink Pharmaceutical Group Co Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a Quick Ratio of 1.21 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. This is near median its historical median of 1.18. Over the past decade, Shenzhen Hepalink Pharmaceutical Group Co's Quick Ratio has ranged from 0.63 to 3.01. According to the industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #573 out of 994 companies in the Drug Manufacturers industry, placing it in the top 57.6%.
Is Shenzhen Hepalink Pharmaceutical Group Co's Quick Ratio too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Quick Ratio of 1.21 is near median its 10-year median of 1.18. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 3.01. The Drug Manufacturers industry median Quick Ratio is 1.45. Shenzhen Hepalink Pharmaceutical Group Co's value of 1.21 is 16.6% below this industry median. Based on the distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #573 out of 994 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #573 out of 994 companies for Quick Ratio. This places Shenzhen Hepalink Pharmaceutical Group Co in the lower half of its industry. The industry median Quick Ratio is 1.45. Shenzhen Hepalink Pharmaceutical Group Co's value of 1.21 is 16.6% below this benchmark. Historically, Shenzhen Hepalink Pharmaceutical Group Co's own Quick Ratio has ranged from 0.63 to 3.01 over the past decade. While the company's 10-year median is 1.18 vs. the industry median of 1.45, Shenzhen Hepalink Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Hepalink Pharmaceutical Group Co's current Quick Ratio of 1.21 is 16.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Hepalink Pharmaceutical Group Co's current Quick Ratio is 1.21, which is near median its own 10-year median of 1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current Quick Ratio of 1.21. The stock's GF Value™ is $0.61, compared to a current price of $0.47 — trading 23% below its estimated fair value. The current Quick Ratio is 1.21, which is near median its 10-year median of 1.18 and 16.6% below the Drug Manufacturers industry median of 1.45. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current Quick Ratio is 1.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of $0.47 is trading 23% below its estimated GF Value™ of $0.61.
Key valuation signals for SHEZF:
Quick Ratio: 1.21 (near median its 10-year median of 1.18)
GF Value™: $0.61 vs. price of $0.47 (23% below fair value)
Industry Position: 16.6% below the Drug Manufacturers median (#573 of 994)
No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Hepalink Pharmaceutical Group Co Business Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
69GF Score
Get the complete analysis for SHEZF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHEZF has been successfully added to your 
